Grant ID RP220468
Awarded On February 16, 2022
Title EIF4A is a new therapeutic vulnerability in triple-negative breast cancer
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization Baylor College of Medicine
Principal Investigator/Program Director Jeffrey M Rosen
Cancer Sites Breast
Contracted Amount $949,208
Lay Summary

Translation of mRNA into protein represents a rate limiting step and is potential therapeutic vulnerability in cancer. The translation of cancer drivers, such as oncogenes and growth factors, is frequently regulated at the level of translation initiation and requires the activity of an RNA helicase eIF4A that facilitates the unwinding of regions of secondary structure at the 5' untranslated region of mRNAs. Many of these mRNAs have longer polypurine-rich 5' UTRs and an increased frequency of upstream open reading frames.

The development of specific eIF4A helicase inhibitor, Zotatifin, by eFFECTOR Therapeutics currently undergoing a Phase I clinical trial, therefore, represents an exciting ne...

Read More